Bilateral adaptive deep brain stimulation is effective in Parkinson's disease

Simon Little, Martijn Beudel, Ludvic Zrinzo, Thomas Foltynie, Patricia Limousin, Marwan Hariz, Spencer Neal, Binith Cheeran, Hayriye Cagnan, James Gratwicke, Tipu Z Aziz, Alex Pogosyan, Peter Brown, Simon Little, Martijn Beudel, Ludvic Zrinzo, Thomas Foltynie, Patricia Limousin, Marwan Hariz, Spencer Neal, Binith Cheeran, Hayriye Cagnan, James Gratwicke, Tipu Z Aziz, Alex Pogosyan, Peter Brown

Abstract

Introduction & objectives: Adaptive deep brain stimulation (aDBS) uses feedback from brain signals to guide stimulation. A recent acute trial of unilateral aDBS showed that aDBS can lead to substantial improvements in contralateral hemibody Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and may be superior to conventional continuous DBS in Parkinson's disease (PD). We test whether potential benefits are retained with bilateral aDBS and in the face of concurrent medication.

Methods: We applied bilateral aDBS in 4 patients with PD undergoing DBS of the subthalamic nucleus. aDBS was delivered bilaterally with independent triggering of stimulation according to the amplitude of β activity at the corresponding electrode. Mean stimulation voltage was 3.0±0.1 volts. Motor assessments consisted of double-blinded video-taped motor UPDRS scores that included both limb and axial features.

Results: UPDRS scores were 43% (p=0.04; Cohen's d=1.62) better with aDBS than without stimulation. Motor improvement with aDBS occurred despite an average time on stimulation (ToS) of only 45%. Levodopa was well tolerated during aDBS and led to further reductions in ToS.

Conclusion: Bilateral aDBS can improve both axial and limb symptoms and can track the need for stimulation across drug states.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Screen shot of 15 s bilateral adaptive deep brain stimulation (aDBS) in patient 1. Bottom two traces are local field potentials (LFPs) after first stage analogue filtering (LFPf1; 3–37 Hz). Third and fourth traces from bottom show LFPs after second stage digital filtering around patient specific β peak (LFPf2; 20±3 Hz). The two traces above are the online readouts of the filtered β amplitude after rectification, smoothing and thresholding. The top two traces show bursts of ramped stimulation in response to β amplitude threshold crossing. Blue and red traces are from left and right electrodes, respectively. Note stimulation across the two sides is discontinuous and independent.
Figure 2
Figure 2
Group mean blinded UPDRS motor scores in the two experimental conditions and their SEs. *Indicates significance with p

Figure 3

Per cent ToS during prolonged…

Figure 3

Per cent ToS during prolonged aDBS after levodopa administration at time 0 and…

Figure 3
Per cent ToS during prolonged aDBS after levodopa administration at time 0 and its dependency on β power. (A) Grey blocks indicate the periods of stable ToS as identified by change-point analysis (p
Similar articles
Cited by
References
    1. Deuschl GL, Schade-Brittinger C, Krack P, et al. . A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;31:896–908. 10.1056/NEJMoa060281 - DOI - PubMed
    1. Deuschl G, Paschen S, Witt K. Clinical outcome of deep brain stimulation for Parkinson's disease. Handbook of clinical neurology; brain stimulation. Amsterdam: Elsevier, 2013. - PubMed
    1. Pradhan SD, Brewer BR, Carvell GE, et al. . Assessment of fine motor control in individuals with Parkinson's disease using force tracking with a secondary cognitive task. J Neurol Phys Ther 2010l;34:32–40. 10.1097/NPT.0b013e3181d055a6 - DOI - PubMed
    1. Kühn AA, Kupsch A, Schneider GH, et al. . Reduction in subthalamic 8–35Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. Eur J Neurosci 2006;23:1956–60. 10.1111/j.1460-9568.2006.04717.x - DOI - PubMed
    1. Ray NJ, Jenkinson N, Wang S, et al. . Local field potential beta activity in the subthalamic nucleus of patients with Parkinson's disease is associated with improvements in bradykinesia after dopamine and deep brain stimulation. Exp Neurol 2008;213:108–13. 10.1016/j.expneurol.2008.05.008 - DOI - PubMed
Show all 27 references
Publication types
MeSH terms
Related information
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 3
Figure 3
Per cent ToS during prolonged aDBS after levodopa administration at time 0 and its dependency on β power. (A) Grey blocks indicate the periods of stable ToS as identified by change-point analysis (p

References

    1. Deuschl GL, Schade-Brittinger C, Krack P, et al. . A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;31:896–908. 10.1056/NEJMoa060281
    1. Deuschl G, Paschen S, Witt K. Clinical outcome of deep brain stimulation for Parkinson's disease. Handbook of clinical neurology; brain stimulation. Amsterdam: Elsevier, 2013.
    1. Pradhan SD, Brewer BR, Carvell GE, et al. . Assessment of fine motor control in individuals with Parkinson's disease using force tracking with a secondary cognitive task. J Neurol Phys Ther 2010l;34:32–40. 10.1097/NPT.0b013e3181d055a6
    1. Kühn AA, Kupsch A, Schneider GH, et al. . Reduction in subthalamic 8–35Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. Eur J Neurosci 2006;23:1956–60. 10.1111/j.1460-9568.2006.04717.x
    1. Ray NJ, Jenkinson N, Wang S, et al. . Local field potential beta activity in the subthalamic nucleus of patients with Parkinson's disease is associated with improvements in bradykinesia after dopamine and deep brain stimulation. Exp Neurol 2008;213:108–13. 10.1016/j.expneurol.2008.05.008
    1. Weinberger M, Mahant N, Hutchison WD, et al. . Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol 2006;96:3248–56. 10.1152/jn.00697.2006
    1. Kühn AA, Tsui A, Aziz T, et al. . Pathological synchronisation in the subthalamic nucleus of patients with Parkinson's disease relates to both bradykinesia and rigidity. Exp Neurol 2009;215:380–7. 10.1016/j.expneurol.2008.11.008
    1. Rosin B, Slovik M, Mitelman R, et al. . Closed-loop deep brain stimulation is superior in ameliorating parkinsonism. Neuron 2011;72:370–84. 10.1016/j.neuron.2011.08.023
    1. Little S, Pogosyan A, Neal S, et al. . Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol 2013;74:449–57. 10.1002/ana.23951
    1. de Solages C, Hill BC, Koop MM, et al. . Bilateral symmetry and coherence of subthalamic nuclei beta band activity in Parkinson's disease. Exp Neurol 2010;221:260–6. 10.1016/j.expneurol.2009.11.012
    1. Little S, Tan H, Anzak A, et al. . Bilateral functional connectivity of the basal ganglia in patients with Parkinson's disease and its modulation by dopaminergic treatment. PLoS ONE 2013;8:e82762 10.1371/journal.pone.0082762
    1. Foltynie T, Hariz MI. Surgical management of Parkinson's disease. Expert Rev Neurother 2010;10:903–14. 10.1586/ern.10.68
    1. Eusebio A, Cagnan H, Brown P. Does suppression of oscillatory synchronisation mediate some of the therapeutic effects of DBS in patients with Parkinson's disease? Front Integr Neurosci 2012;6:47 10.3389/fnint.2012.00047
    1. Goetz CG, Tilley BC, Shaftman SR, et al. . Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–70. 10.1002/mds.22340
    1. Taylor WA.2000. Change-point analysis: a powerful new tool for detecting changes. .
    1. Castrioto A, Lozano AM, Poon YY, et al. . Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol Psychiatry 2011;68:1550–6. 10.1001/archneurol.2011.182
    1. Ford B, Winfield L, Pullman SL, et al. . Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up. J Neurol Neurosurg Psychiatr 2004;75:1255–9. 10.1136/jnnp.2003.027557
    1. Schuepbach WM, Rau J, Knudsen K, et al. . Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610–22. 10.1056/NEJMoa1205158
    1. Lempka SF, Miocinovic S, Johnson MD, et al. . In vivo impedance spectroscopy of deep brain stimulation electrodes. J Neural Eng 2009;6:046001 10.1088/1741-2560/6/4/046001
    1. Rosa M, Marceglia S, Servello D, et al. . Time dependent subthalamic local field potential changes after DBS surgery in Parkinson's disease. Exp Neurol 2010;222:184–90. 10.1016/j.expneurol.2009.12.013
    1. Abosch A, Lanctin D, Onaran I, et al. . Long-term recordings of local field potentials from implanted deep brain stimulation electrodes. Neurosurgery 2012;71:804–14. 10.1227/NEU.0b013e3182676b91
    1. Lopiano L, Torre E, Benedetti F, et al. . Temporal changes in movement time during the switch of the stimulators in Parkinson's disease patients treated by subthalamic nucleus stimulation. Eur Neurol 2003;50:94–9. 10.1159/000072506
    1. Keresztenyi Z, Valkovic P, Eggert T, et al. . The time course of the return of upper limb bradykinesia after cessation of subthalamic stimulation in Parkinson's disease. Parkinsonism Relat Disord 2007;13:438–42. 10.1016/j.parkreldis.2006.12.003
    1. Cooper SE, Noecker AM, Abboud H, et al. . Return of bradykinesia after subthalamic stimulation ceases: relationship to electrode location. Exp Neurol 2011;231:207–13. 10.1016/j.expneurol.2011.06.010
    1. Chen CC, Brücke C, Kempf F, et al. . Deep brain stimulation of the subthalamic nucleus: a two-edged sword. Curr Biol 2006;16:R952–3. 10.1016/j.cub.2006.10.013
    1. Brittain JS, Sharott A, Brown P. The highs and lows of beta activity in cortico-basal ganglia loops. Eur J Neurosci 2014;39:1951–9. 10.1111/ejn.12574
    1. Giannicola G, Rosa M, Servello D, et al. . Subthalamic local field potentials after seven-year deep brain stimulation in Parkinson's disease. Exp Neurol 2012;237:312–17. 10.1016/j.expneurol.2012.06.012

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner